Important Update for Iovance Biotherapeutics Investors
The Gross Law Firm is sending a crucial notice to shareholders of
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) regarding a class action lawsuit that could significantly impact your investment. If you purchased shares of Iovance between
May 9, 2024, and
May 8, 2025, it is essential to take note of the upcoming deadline to join this legal proceeding:
July 14, 2025.
Background on the Case
The allegations outlined in the lawsuit state that throughout the specified class period, the defendants provided encouraging statements to investors while concealing adverse facts about the company’s true growth potential. This information became critical when, on
July 25, 2024, Iovance had to revise its revenue guidance for the full fiscal year, attributing the disappointing financial results to several factors, including maintenance performed on their iCTC, which drastically reduced operational capacity, and lower-than-expected sales of
Proleukin. This news led to a shocking decline in Iovance's stock price, which plummeted from
$3.17 to
$1.75 per share—a staggering drop of approximately
44.8% within a single day.
How to Participate
Shareholders who meet the requirements and wish to engage in this class action must register their information through the dedicated form provided by the law firm. Importantly, while stakeholders are encouraged to seek lead plaintiff status, this is not a prerequisite for participation in the recovery process. For registration, visit the following link:
Register Here.
Once registered, shareholders will be equipped with portfolio monitoring software that provides status updates throughout the lifecycle of the case. This feature ensures you stay informed about any developments, helping you make the best decisions regarding your investments.
Why You Should Act Now
Given the dramatic drop in stock price and the severity of the allegations, it is crucial for investors to take action without delay. The deadline for registration is fast approaching, and participation in this class action can provide a path for recourse against potential misconduct by the company. Acting promptly not only secures your place in this legal effort but also empowers collective action to seek accountability.
Assurance of No Cost
The Gross Law Firm clarifies that there is no cost or obligation associated with participating in the case. Their commitment to safeguarding the rights of investors who may have suffered due to deceitful practices is unwavering. They seek to hold companies accountable for their responsibilities towards their shareholders, ensuring that corporate practices adhere to established standards of integrity and transparency.
For more inquiries or to learn about additional resources, interested parties can reach out directly to the Gross Law Firm:
- - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
- - Email: [email protected]
- - Phone: (646) 453-8903
Conclusion
The coming weeks will be crucial for investors in Iovance Biotherapeutics. With the potential for significant financial recovery on the line, we urge you to take action before the
July 14, 2025 deadline. Join the class action and ensure your rights as a shareholder are protected as this case unfolds.
Stay informed, act quickly, and secure your investment interests with the Gross Law Firm's expert guidance.